Breaking News, Collaborations & Alliances

Airway Therapeutics and Celonic Enter COVID-19 Collaboration

Will make AT-100 as promising new candidate for coronavirus, production expected to begin in June

By: Contract Pharma

Contract Pharma Staff

Airway Therapeutics and Celonic Group, a biopharmaceutical CDMO specialized in the development and production of advance therapy medicinal products (ATMPs) and mammalian cell line-expressed biotherapeutics, have formed a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19. Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study. Production of AT-100 is expe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters